Michael's main focus areas are the planning, development, implementation and evaluation of benefit-risk management solutions, as well as the optimization of processes around signal and benefit-risk management. He is engaged in developing and applying (benefit-) risk analysis and signal management methodologies in order to make RM planning more formally reproducible. Furthermore, he supports the development, implementation and evaluation of effectiveness of additional risk minimization and PV measures in the context of RMPs, as well as post-authorization studies to optimize the benefit-risk profiles of medicines.

Jillian has over 20 years of experience in the pharmaceutical/biotech industry and is currently Associate Director, Global Risk Management at Jazz Pharmaceuticals. Prior to her current role, she held various positions across R&D in preclinical safety assessment, regulatory affairs, project management, benefit-risk evaluation, clinical safety/pharmacovigilance, and risk management. She is currently supporting the American Statistical Association Biopharmaceutical Section Safety Scientific Working Group (Workstream 1) Benefit Risk Assessment Planning (BRAP) Taskforce.